Related references
Note: Only part of the references are listed.Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Comment on 'Predicting the response to infliximab from trough serum levels'
K. Bendtzen et al.
GUT (2010)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Biological Therapies for Inflammatory Bowel Diseases
Paul Rutgeerts et al.
GASTROENTEROLOGY (2009)
Incidence and Clinical Significance of Immunogenicity to Infliximab in Crohn's Disease: A Critical Systematic Review
Andrea Cassinotti et al.
INFLAMMATORY BOWEL DISEASES (2009)
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
Klaus Bendtzen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement
Lucien Aarden et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
M. Svenson et al.
RHEUMATOLOGY (2007)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006
M. Clark et al.
GASTROENTEROLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
Klaus Bendtzen et al.
ARTHRITIS AND RHEUMATISM (2006)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease
S Candon et al.
CLINICAL IMMUNOLOGY (2006)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Anti-IFN BAb and NAb antibodies - A minireview
K Bendtzen
NEUROLOGY (2003)
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
RJ Farrell et al.
GASTROENTEROLOGY (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
F Cornillie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs
C Hennig et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)